Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TD-9855 in adults with ADHD
NCT01458340Phase 2Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Dec 2011
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ampreloxetine in attention deficit hyperactivity disorder (ADHD), sponsored by Theravance Biopharma, Inc.. Started Dec 2011; status: completed.
02
Drugs
ampreloxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT01458340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01458340.